High-affinity inhibitors of dihydrofolate reductase: Antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size

Journal of Medicinal Chemistry

Volumn 39, Issue 4, 1996, Pages 892-903

  Kuyper, Lee F ^a   Baccanari, David P ^a   Jones, Michael L ^a   Hunter, Robert N ^a   Tansik, Robert L ^a   Joyner, Suzanne S ^a   Boytos, Christine M ^a   Rudolph, Sharon K ^a   Knick, Vince ^a   Wilson, H Robert ^a   Caddell, J Marc ^a   Friedman, Henry S ^b   Comley, John C W ^c   Stables, Jeremy N ^c  

^a GLAXOSMITHKLINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIAMINO 7 (1 ETHYLPROPYL) 7H PYRROLO[3,2 F]QUINAZOLINE; 1,3 DIAMINO 7 (1 ETHYLPROPYL) 8 METHYL 7H PYRROLO[3,2 F]QUINAZOLINE; DIHYDROFOLATE REDUCTASE INHIBITOR; GLYCOPROTEIN P; METHOTREXATE; PIRITREXIM; PYRROLO[3,2 F]QUINAZOLINE DERIVATIVE; TRIMETREXATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANDIDIASIS; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG TUMOR; MALE; MOLECULAR SIZE; MOUSE; MULTIDRUG RESISTANCE; NEPHRITIS; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANDIDIASIS; CELL DIVISION; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICE, NUDE; MICE, SCID; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; P-GLYCOPROTEIN; PNEUMONIA, PNEUMOCYSTIS; PROTEIN STRUCTURE, SECONDARY; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TOXOPLASMA; TUMOR CELLS, CULTURED;

EID: 13344275848     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9505122     Document Type: Article

References (79)

1. Schweitzer, B. I.; Dicker, A. P.; Bertino, J. R. Dihydrofolate reductase as a therapeutic target. FASEB J. 1990, 4, 2441-2452.
2. Kuyper, L. F. Inhibitors of dihydrofolate reductase. In Computer-Aided Drug Design; Perun, T. J., Propst, C. L., Eds.; Marcel Dekker Inc.: New York, 1989; pp 327-369.
3. Bertino, J. R. Karnofsky Memorial Lecture: Ode to methotrexate. J. Clin. Oncol. 1993, 11, 5-14.
4. Fleming, G. F.; Schilsky, R. L. Antifolates: The next generation. Semin. Oncol. 1992, 19, 707-719.
5. Sirotnak, F. M., Burchall, J J., Ensrninger, W. B , Montgomery, J. A., Eds. Folate Antagonists as Therapeutic Agents; Academic Press: New York, 1984.
6. Roth, B.; Cheng, C. C. Recent progress in the medicinal chemistry of 2,4-diaminopyrimidines. In Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier Biomedical Press: Amsterdam, 1982; Vol. 19, pp 269-331.
7. Salter, A. J. Trimethoprim-sulfamethoxazole: An assessment of more than 12 years of use. Rev. Infect. Dis. 1982, 4, 196-236.
8. Hitchings, G. H. The metabolism of plasmodia and the chemotherapy of malarial infections. In Tropical Medicine from Romance to Reality; Wood, C., Ed.; Academic Press: London, 1978; pp 79-98.
9. Allegra, C. J.; Chabner, B. A.; Tuazon, C. U.; Ogata-Arakaki, D.; Baird, B.; Drake, J. C.; Simmons, J. T., Lack, E. E., Shelhamer, J. H.; Balis, F.; Walker, R.; Kovacs, J. A.; Lane, H. C.; Masur, H. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med 1987, 317, 978-985.
10. Falloon, J.; Allegra, C.; Kovacs, J.; O'Neill, D.; Ogata-Arakaki, D.; Feuerstein, I.; Polis, M.; Davey, R.; Lane, H. C., LaFon, S.; Rogers, M.; Zunich, K.; Zurio, J.; Tuazon, C.; Parenti, D.; Simon, G.; Masur, H Piritrexim with leucovorin for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Clin. Res 1990, 38, 361A.
11. Rosowsky, A.; Hynes, J. B.; Queener, S. F. Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1995, 39, 79-86.
12. Kovacs, J. A.; Allegra, C. J.; Masur, H. Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii Exp. Parasitol. 1990, 71, 60-68.
13. Derouin, F.; Chastang, C. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob. Agents Chemother. 1989, 33, 1753-1759.
14. Baccanari, D. P.; Tansik, R. L.; Joyner, S. S ; Fling, M. E.; Smith, P. L.; Freishheim, J. H. Characterization of Candida albicans dihydrofolate reductase. J. Biol. Chem. 1989, 264, 1100-1107.
15. Edwards, J. E. Invasive Candida infections. Evolution of a fungal pathogen. N. Engl. J. Med. 1991, 324, 1060-1062.
16. Leoung, G., Mills, J., Eds. Opportunistic Infections in Patients with the Acquired Immunodeficiency Syndrome; Marcel Dekker: New York, 1989.
17. Sternberg, S. The emerging fungal threat. Science 1994, 266, 1632-1634.
18. Jolivet, J.; Cowan, K. H.; Curt, G. A.; Clendeninn, N. J.; Chabner, B. A. The pharmacologv and clinical use of methotrexate. N. Engl. J. Med. 1983, 309, 1094-1104.
19. Dembo, M.; Sirotnak, F. M. Membrane transport of folate compounds in mammalian cells. In Folate Antagonists as Therapeutic Agents; Sirotnak, J. M., Burchall, J. J., Ensminger, W. B., Montgomery, J. A., Eds.; Academic Press: New York, 1984; Vol. 1, pp 173-217.
20. Henderson, G. B. Transport of folate compounds into cells. In Nutritional, Pharmacologic and Physiologic Aspects of Folates and Pterins; Blakeley, E. I., Whitehead, M. V., Eds.; Wiley New York, 1986; pp 207-250.
21. Sirotnak, F. M. Determinants of resistance to antifolates: Biochemical phenotypes, their frequency of occurence and circumvention. Natl. Cancer Inst. Monogr. 1987, 5, 27-35.
22. Cavallito, J. C.; Nichol, C. A.; Brenckman, W. D., Jr.; Deangelis, R. L., Stickney, D. R.; Simmons, W. S.; Sigel, C. W. Lipid-soluble inhibitors of dihydrofolate reductase I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab. Dispos. 1978, 6, 329-337.
23. Sigel, C. W.; Macklin, A. W.; Woolley, J. L., Jr.; Johnson, X. W.; Collier, M. A.; Blum, M. R.; Clendenin, N. J.; Everitt, B. J. M.; Grebe, G.; Mackars, A.; Foss, R. G.; Duch, D. S.; Bowers, S. W.; Nichol, C. A. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. Natl. Cancer Instit. Monogr. 1987, 5, 111-120.
24. Lin, J. T.; Bertino, J. R. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest. 1991, 9, 159-172.
25. Fulton, B.; Wagstaff, A. J.; McTavish, D. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs 1995, 49, 563-576.
26. Kovacs, J. A.; Allegra, C. J.; Swan, J. C.; Drake, J. C ; Parrillo, J. E.; Chabner, B. A.; Masur, H. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob. Agents Chemother. 1988, 32, 430-433.
27. Queener, S. F.; Bartlett, M. S.; Jay, M. A.; Durkin, M. M.; Smith, J. W. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis cannii in culture and in a rat model of infection. Antimicrob. Agents Chemother. 1987, 31, 1323-1327.
28. Sattler, F. R.; Allegra, C. J.; Verdegem, T D.; Akil, B ; Tuazon, C. U.; Hughlett, C.; Ogata-Arakaki, D.; Feinberg, J.; Shelhamer, J.; Lane, H. C.; Davis, R.; Boylen, C. T.; Leedom, J. M.; Masur, H. Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocyctis carinii pneumonia. J. Infect. Dis. 1990, 161, 91-96.
29. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
30. Ledig, K. W. 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines. U.S. Patent 4,118,561, 1978.
31. Jones, M. L.; Kuyper, L F ; Styles, V. L.; Caddell, J. M Lewis acid assisted cyclization of arylcyanoguanidines to 2,4-diaminoquinazolines. J. Heterocycl. Chem. 1994, 31, 1681-1683.
32. Parr, W. J. E. Synthesis of selenium-containing para-phenylenediamines: Novel antidegradants for natural rubber. J Chem. Soc., Perkin Trans. 1 1981, 3002-3007.
33. Verardo, G.; Giumanini, A. G.; Strazzolini, P.; Poiana, M. Reductive N-monoalkylation of primary aromatic amines. Synthesis 1993, 121-125.
34. Kotsuki, H ; Kobayashi, S.; Matsumoto, K.; Suenaga, H.; Nishizawa, H. High Pressure Organic Chemistry; XII. A Convenient Synthesis of Aromatic Amines from Activated Aromatic Fluorides. Synthesis 1990, 1147-1148.
35. Suhr, H. Nueleophilic substitution, V. Reaction of 4-nitrofluorobenzene with primary amines Justus Liebigs Ann. Chem. 1965, 687, 175-182.
36. Peters, A. T., Soboyejo, N. Iodo-substituted 4-aminoazobenzenes and 4-phenylazonaphthylamines - dyes for synthetic-polymer fibres. J. Soc. Dyers Colour. 1988, 104, 486-491.
37. Bui, N. M.; Gillet, R.; Dumont, P. An improved synthesis of 5-iodo-2′-deoxyuridine-I131 and 5-iodouracil-I131. Int. J. Appl. Radiat. Isot. 1965, 16, 337-339.
38. Heck, R. F. Palladium Reagents in Organic Syntheses; Academic Press. London, 1985.
39. Sakamoto, T.; Kondo, Y.; Iwashita, S.; Nagano, T.; Yamanaka, H Condensed heteroaromatic ring systems. XIII. One-step synthesis of 2-substituted 1-methylsulfonylindoles from N-(2-halophenyl)methanesulfonamides. Chem. Pharm. Bull. 1988, 36, 1305-1308.
40. Arcadi, A ; Cacchi, S ; Marinelli, F. Palladium-catalysed coupling of aryl and vinyl triflates or halides with 2-ethynylaniline: An efficient route to functionalized 2-substituted indoles. Tetrahedron Lett. 1989, 30, 2581-2584.
41. Blaney, J. M.; Hansch, C.; Silipo, C.; Vittoria, A. Structure-activity relationships of dihydrofolate reduetase inhibitors. Chem. Rev. 1984, 84, 333-407.
42. Champness, J. N.; Kuyper, L. F.; Beddell, C. R. Interaction between dihydrofolate reductase and certain inhibitors. In Topics in Molecular Pharmacology; Burgen, A. S. V., Roberts, G. C. K., Tute, M. S., Eds.; Elsevier: New York, 1986; Vol. 3, pp 335-362.
43. Kraut, J.; Matthews, D. A. Dihydrofolate reductase. In Biological Macromolecules and Assemblies; Jurnak, F. A., McPherson, A., Eds.; Wiley: New York, 1987, Vol. 3, pp 1-71.
44. Freisheim, J. H.; Matthews, D. A. The comparative biochemistry of dihydrofolate reductase. In Folate Antagonists as Therapeutic Agents; Sirotnak, F. M., Burchall, J. J., Ensminger, W. D., Montgomery, J. A., Eds.; Academic Press: New York, 1984; Vol. 1, pp 69-131.
45. Champness, J. N.; Achari, A.; Ballantine, S. P.; Bryant, P. K.; Delves, C. J.; Stammers, D. K. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. Structure 1994, 2, 915-924.
46. McCormack, J. J.; Allen, B. A.; Ledig, K. W.; Hillcoat, B. L. Inhibition of dihydrofolate reductases by derivatives of 2,4-diaminopyrroloquinazoline. Biochem. Pharmacol. 1979, 28, 3227-3229.
47. Castaldo, R. A.; Gump, D. W.; McCormack, J. J. Activity of 2,4-diaminoquinazoline compounds against Candida species. Antimicrob. Agents Chemother. 1979, 15, 81-86.
48. Whitlow, M.; Howard, A. J.; Stewart, D.; Hardman, K. D.; Kuyper, L. F.; Baccanari, D. P.; Fling, M.; Tansik, R. Unpublished results.
49. van der Bliek, A. M.; Borst, P. Multidrug resistance. Adv. Cancer Res. 1989, 52, 165-203.
50. Gottesman, M. M.; Pastan, I. The multidrug transporter, a double-edged sword. J. Biol. Chem. 1988, 263, 12163-12166.
51. Zamora, J. M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 1988, 33, 454-462.
52. Klohs, W. D.; Steinkampf, R. W.; Besserer, J. A.; Fry, D W. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U. Cancer Lett 1986, 31, 253-260.
53. Assaraf, Y. G.; Molina, A.; Schimke, R. T. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. J. Natl. Cancer Inst. 1989, 81, 290-294.
54. Selassie, C. D.; Hansch, C.; Khwaja, T. A. Structure-activity relationships of antineoplastic agents in multidrug resistance. J. Med. Chem. 1990, 33, 1914-1919.
55. McGrath, J. P.; Varshavsky, A. The yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-glycoprotein. Nature 1989, 340, 400-404.
56. Raymond, M.; Gros, P.; Whiteway, M.; Thomas, D. Y. Functional complementation of yeast ste6 by a mammalian multidrug resistance mdr gene. Science 1992, 256, 232-234.
57. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D., Rittman-Grauer, L.; Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl Acad. Sci. U.S.A. 1989, 86, 695-698.
58. Baccanari, D. P.; Tansik, R. L. Multiple drug resistance and its relationship to brain penetration by lipophilic dihydrofolate reductase inhibitors. Proc. Am. Assoc. Cancer Res. 1990, 31, 339.
59. Hill, B. T.; Price, L. A. DDMP (2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine). Cancer Treat. Rev. 1980, 7, 95-112.
60. Duch, D. S.; Edelstein, M. P.; Nichol, C. A. Inhibition of histamine-metabolizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists. Mol. Pharmacol. 1980, 18, 100-104.
61. Luft, B. J.; Remington, J. S. AIDS commentary: toxoplasmic encephalitis. J. Infect. Dis. 1988, 157, 1-6.
62. Frenkel, J. K.; Hitchings, G. H. Relative reversal by vitamins (p-aminobenzoic, folic, and folinic acids) of the effects of sulfadiazine and pyrimethamine on Toxoplasma, mouse and man. Antibiot. Chemother. 1957, 7, 630-638.
63. Delves, C. J.; Ballantine, S. P.; Tansik, R. L.; Baccanari, D. P.; Stammers, D. K. Refolding of recombinant Pneumocystis carinii dihydrofolate reductase and characterization of the enzyme. Protein Express. Purif. 1993, 4, 16-23.
64. Hughes, W. T. Comparison of dosages, intervals, and drugs in prevention of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 1988, 32, 623-625.
65. Ruskin, J.; LaRiviere, M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991, 337, 468-471.
66. Roth, B.; Strelitz, J. Z. The protonation of 2,4-diaminopyrimidines. I. Dissociation constants and substituent effects. J. Org. Chem. 1969, 34, 821-836.
67. Cha, S. Tight-binding inhibitors - 1: Kinetic behavior. Biochem. Pharmacol. 1975, 24, 2177-2185.
68. Henderson, P. J. F. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochemistry 1972, 127, 321-323.
69. Baccanari, D. B.; Joyner, S. S. Dihydrofolate reductase hysteresis and its effect on inhibitor binding analyses. Biochemistry 1981, 20, 1710-1716.
70. Delcamp, T. J.; Susten, S. S.; Blankenship, D. T.; Freisheim, J. H. Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells. Biochemistry 1983, 22, 633-639.
71. Krug, E. C.; Marr, J. J.; Berens, R. L. Purine metabolism in Toxoplasma gondii. J. Biol. Chem. 1989, 264, 10601-10607.
72. Carmichael, J.; Mitchell, J. B.; DeGraff, W. G.; Gamson, J.; Gazdar, A. F.; Johnson, B. E.; Glatstein, E.; Minna, J. D. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br. J. Cancer 1988, 57, 540-547.
73. Skehan, P.; Storeng, R.; Scudiero, D ; Monks, A.; MacMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
74. Ou-Yang, K.; Krug, E. C.; Marr, J. J.; Berens, R. L. Inhibition of growth of Toxoplasma gondii by qinghasosu and derivatives. Antimicrob. Agents Chemother. 1990, 34, 1961-1965.
75. McLemore, T. L.; Eggleston, J. C.; Shoemaker, R. H.; Abbott, B. J.; Bohiman, M. E.; Liu, M. C.; Fine, D. L.; Mayo, J. G.; Boyd, M. R. Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res. 1988, 48, 2880-2886.
76. Wang, A. M.; Elion, G. B.; Friedman, H. S.; Bodell, W. J.; Bigner, D. D.; Schold, S. C. Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother. Pharmacol. 1991, 27, 278-284.
77. Comley, J. C. W.; Sterling, A. M. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J. Eukaryot. Microbiol. 1994, 41, 540-546.
78. Comley, J. C. W.; Sterling, A. M. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii Pneumonia in SCID mice. Antimicrob. Agents Chemother. 1995, 39, 806-811.
79. Foss, R. G.; Sigel, C. W. Lipid-soluble inhibitors of DHFR. III: Quantitative thin-layer and high performance liquid chromatographic methods of the measurement of plasma concentrations of the antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine. J. Pharm. Sci. 1982, 71, 1176-1178